Development Pharmaceuticals-B (09939.HK): KT-939 has shown promising mid-term safety data in human trials and has initiated a new raw material registration application.

Wisdom Financial News App News, Exploring Pharmaceuticals -B (09939.HK) announced that the long-term safety trial of KT-939 in humans has been completed with all subjects enrolled in September 2025. This long-term safety trial is an open-label, single-arm, single-center study designed to evaluate the potential for adverse reactions in human skin caused by long-term use of cosmetics containing KT-939 ingredients, with a primary focus on the safety of 0.2% KT-939 applied topically for 52 weeks.